Inari Medical (NASDAQ:NARI – Get Free Report) and Sharps Technology (NASDAQ:STSS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk and valuation.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Inari Medical and Sharps Technology, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Inari Medical | 0 | 6 | 5 | 0 | 2.45 |
| Sharps Technology | 0 | 0 | 0 | 0 | 0.00 |
Inari Medical currently has a consensus target price of $58.89, suggesting a potential upside of 15.85%. Given Inari Medical’s stronger consensus rating and higher possible upside, analysts clearly believe Inari Medical is more favorable than Sharps Technology.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Inari Medical | $493.63 million | 6.03 | -$1.64 million | ($1.35) | -37.65 |
| Sharps Technology | N/A | N/A | -$9.84 million | ($8.08) | -0.48 |
Inari Medical has higher revenue and earnings than Sharps Technology. Inari Medical is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Inari Medical has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Sharps Technology has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
Profitability
This table compares Inari Medical and Sharps Technology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Inari Medical | -13.68% | -10.09% | -6.60% |
| Sharps Technology | N/A | -110.40% | -73.60% |
Institutional & Insider Ownership
91.0% of Inari Medical shares are held by institutional investors. Comparatively, 17.2% of Sharps Technology shares are held by institutional investors. 10.6% of Inari Medical shares are held by insiders. Comparatively, 8.7% of Sharps Technology shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Inari Medical beats Sharps Technology on 10 of the 13 factors compared between the two stocks.
About Inari Medical
Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
About Sharps Technology
Sharps Technology, Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. Sharps Technology, Inc. was incorporated in 2017 and is based in Melville, New York.
Receive News & Ratings for Inari Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inari Medical and related companies with MarketBeat.com's FREE daily email newsletter.
